We are Missing the Neurocognitive Consequences of Chemotherapy-Induced Hearing Loss in Pediatric Brain Tumor Survivors

Abstract

Current treatment for pediatric brain tumors has resulted in increased survival rates, such that we are now positioned to consider the quality of survivorship1,2. A common treatment regimen includes surgery, radiation, and chemotherapy – specifically, platinum-based drugs3. Use of  platinum-based chemotherapy is associated with ototoxicity. Roughly 60% of pediatric brain tumor survivors treated with platinum-based drugs sustain hearing loss2,4. This hearing loss, which can persist and worsen over time5 can also negatively impact academics and overall quality of life in these developing children6. This systematic review summarizes current research on the cognitive effects of chemotherapy-induced hearing loss, both during and after treatment.